Last reviewed · How we verify
HIPEC with Mitomycin-C
At a glance
| Generic name | HIPEC with Mitomycin-C |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Anemia
- Hypophosphatemia
- Hypoalbuminemia
- Lymphocyte count decreased
- Grade II
- Aspartate aminotransferase increased
- Alanine aminotransferase increased
- Hypotension
- Abdominal pain
- Pain
- Fever
- Sinus tachycardia
Key clinical trials
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis (PHASE2)
- Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining) (PHASE2)
- Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP) (PHASE3)
- ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis (PHASE2)
- Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer
- Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HIPEC with Mitomycin-C CI brief — competitive landscape report
- HIPEC with Mitomycin-C updates RSS · CI watch RSS
- Memorial Sloan Kettering Cancer Center portfolio CI